Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Oversubscribed Series C round garners $72mm for SQZ Biotechnologies

Executive Summary

SQZ Biotechnologies Co. (cell therapies for cancer and autoimmune diseases) raised $72mm through an oversubscribed Series C round. New investors Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group were joined by returning backers Bridger Healthcare Partners, Global Health Science Fund (Quark), GV, JDRF T1D Fund, NanoDimension, and Polaris. Bridger and Quark join SQZ's board. Proceeds will fund ongoing development activities including work on a lead project in antigen presenting cells for HPV-positive cancers.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies